Lutris Pharma today announced that it has expanded the intellectual property (IP) surrounding its novel B-Raf inhibitors.
Broad Patents Include Compositions of Novel B-Raf Inhibitors and Use for the Treatment of Cutaneous Reactions Caused by Treatment with EGFR Inhibitors and/or PI3K Inhibitors |
| [08-December-2021] |
|
TEL AVIV, Israel, Dec. 8, 2021 /PRNewswire/ -- Lutris Pharma, a clinical stage biopharmaceutical company focused on improving anti-cancer therapies by reducing dose limiting side effects, today announced that it has expanded the intellectual property (IP) surrounding its novel B-Raf inhibitors, including lead compound LUT014, a topically applied, novel B-Raf inhibitor for the treatment of cutaneous reactions caused by treatment with epidermal growth factor receptor (EGFR) inhibitors and/or PI3K inhibitors and treatment of radiation dermatitis (RD) caused by radiation therapy, in both the U.S. and internationally. Within its patent portfolio, Lutris currently has a total of 13 issued national patents covering eight countries, as well as 17 patents pending.
The company’s patent portfolio includes compositions comprising BRaf inhibitors and uses thereof for treating and/or preventing, by topical or systemic administration, cutaneous conditions caused by treatment with EGFR inhibitors and/or PI3K inhibitors, which have been granted in the U.S. Israel, Canada Russia, Australia, Japan, Mexico and Korea, with other applications still in active prosecution. Additional non-U.S. applications have been accepted for expedited examination based on the allowed U.S. applications under the Patent Prosecution Highway program. The company noted that a patent has been filed in the U.S., Australia, Brazil, Canada, China, EP (regional), Israel, India, Japan, Mexico, Russian Federation, South Korea and South Africa for the treatment of radiation dermatitis (RD) with B-Raf inhibitors. Lutris also has additional provisional patents for dosing and novel indications. A broad U.S. patent has been granted for a method of screening a population of B-Raf inhibitors in order to identify the best candidates for clinical development. “The expansion of our patent portfolio, for which we have filed broadly and have received key levels of protection, is a critical focus for the company, as we seek to continually strengthen the position around LUT014,” stated Noa Shelach, Ph.D., Chief Executive Officer of Lutris Pharma, “Our pipeline programs are based on novel technology, backed by compelling data, illustrating the potential ability to harness the paradoxical effect of B-Raf inhibitor therapy with a topical treatment (LUT014) that can both reverse the inhibitory effect of EGFR inhibitors on downstream proteins in the skin cells in order to reduce dose-limiting acneiform lesions caused by EGFR therapy, and stimulate proliferation of basal keratinocytes to treat cancer patients afflicted with radiation dermatitis. Our current phase 2 trial of LUT014 in metastatic colorectal cancer patients (mCRC) being treated with EGFR inhibitor therapy who have developed dose-limiting acneiform lesions is progressing and we expect to report rolling data, as appropriate. Additionally, we look forward to announcing data from our blinded phase 1/2 study of LUT014 for the treatment of RD in breast cancer patients, during the first half of 2022. We are dedicated to making an impact on these patients, for whom there are currently no approved treatment options.” Additional information on the patent portfolio can be found on “Intellectual Property” section of the Lutris website at: www.lutris-pharma.com/intellectual-property. About LUT014 About Lutris Pharma Contacts: Lutris Pharma Rx Communications Group
SOURCE Lutris Pharma |
View original content to download multimedia:
